Petros Pharmaceuticals, Inc. (PTPI) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in New York City, NY, United States. The current CEO is Fady Boctor.
PTPI has IPO date of 2020-12-02, 18 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $180.73K.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
